Endocrine Abstracts

Medical documentation of 976 patients treated and followed-up over the years 2001–2006 at our 131- radioiodine treatment centre was analysed with respect to their thyroid cancer staging. The mean age at their time of diagnosis was 59±15.1 years. From histopathology, papillary, follicular or poorly differentiated cancer was diagnosed in 87.6, 11.7, and 0.7% of these patients, respectively. The mean ages of patients with papillary, follicular or poorly differentiated c...

Introduction: It has been shown that thyroid cancer has a significant correlation with cancers originated from other organs. The aim of this study was to investigate the association between synchronous primary cancers in patients with thyroid cancer.Material and Method: A retrospective analysis of medical records of 560 thyroid cancer patients treated in the years 2007–2013 and followed up over 2–8 years, was performed. In 38 patients (6.7%), 5...

The increase in thyroid disease frequency has been observed recently. It may be attributed to the changing iodine status, endocrine disruptors, as well as better availability of ultrasound and laboratory tests. The aim of the study was to assess the occurrence of newly recognized thyroid diseases during long-term follow-up.Material and methods: Study was carried out in 2010–2012 in Krakow area. It included 266 patients aged 23–81 years (168 fem...

Background: Renal hyperparathyroidism (rHPT) may affect up to 30% of dialysispatients with end-stage renal disease (ESRD). rHPT is associated with an increased risk of cardiovascular events (CE) and bone diseases such as pain or renal osteodystrophy. Total or subtotal parathyroidectomy may be a chance to reduce the severity of the symptoms and decrease the risk of CE and death. Pre-operative scintigraphy and ultrasound diagnostics in rHPT may be insufficient at even up to 60% ...

Background: Carcinoid crisis (CC) may rarely occur as a complication of general anesthesia/surgery or peptide receptor radionuclide therapy (PRRT) in patients with neuroendocrine tumor (NET). The incidence of CC as a complication of PRRT is underestimated and comes to 10% of all radioisotope therapies. Progressive organ dysfunction, decrease or increase in blood pressure SBP <80 mmHg or >180 mmHg, unexplained tachyarrhythmia with heart rate >120/ min, bronchoconstr...

Introduction: The good expression of somatostatin receptors in neuroendocrine tumor tissue enables effective treatment with peptide receptor radionuclide therapy (PRRT). To date, there is no clear consensus on the optimal PRRT arrangement due to the possibility of the use of different radiopharmaceutical regimens. In theory, the simultaneous use of two radionuclides (90Y and 177Lu) with different energy and radiation ranges should be more effective than monotherapy. The main o...